The most common and second-highest death rate amongst all cancers is breast cancer (BC). Artificial intelligence (AI) has transformed the care of BC by enhancing the evaluation of risk, clinical assessment, rapid identification, personalized medicine, and therapeutic effect prognosis. Atomic therapy has exploited AI for almost 50 years, but further current breakthroughs in deep learning (DL) and machine learning (ML) have given AI in radioactive therapy increased possibilities. Some factors include genetic factors, dietary factors, customized risk assessment, and environmental factors which are useful for AI in the assessment of BC, and it also suggests more accurate testing for BC patients who are at higher risk. Enhancing the difficulties with data privacy, data reliability, health data, medical information technology systems, and ethical issues creates problems in applying AI in medicine; as a result, awareness and ongoing oversight are necessary. Given artificial intelligence’s tremendous promise in the therapy of BC, its moral and practical ramifications must be carefully considered.